Jane Wan

Hope abounds for local drug discovery companies despite challenges at home.

The spate of drug scandals may alter the relationship between manufacturers and research institutions, and reshape Japan’s clinical research industry.

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.

The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.

Quality assurance of biological products is central to India's good distribution practices guidelines.

Domestic companies are changing their business models in response to recent drug price cuts.

Foreign firms struggle against stricter patent laws, but all is not lost.

After a series of government reforms that are appealing to both domestic and foreign players, the Japanese pharmaceutical market is making a comeback.

New price-control policy has domestic and global firms waiting on the sidelines to launch products.

China's drug-distribution network has been a mess for years, but government reforms and industry focus are unveiling new opportunities for market order and growth.

Packaging is indeed headed to be a lead sector in the Asian pharmaceutical environment, but certain challenges must first be overcome.

Contract manufacturing organizations throughout Asia are increasing their capabilities to meet market demand and attract foreign investment and partnerships.

The contract-research industry in China is growing in leaps and bounds, and Big Pharma is leading the way.

Global pharmaceutical companies have much to gain in Asia, and the good news is that it's a two-way street. Firms based in Asia are also expected to grow at the global level.

Manufacturers and regulators on both sides of the ocean move to ensure the safety of heparin and other globally distributed drug products.

As demand for global vaccine development and production grows, all eyes are turning to Asia.

New pricing controls and healthcare reforms may be pushing the pharmaceutical market out of this southeast Asian country. This article contains bonus online-exclusive material.

China's State Food and Drug Administration has completed a new draft of GMP guidelines, but after a series of quality-control events, it will take time for the country to regain the global pharmaceutical industry's trust.

The Japanese government is eager to jumpstart its generic-drug market, but changes must come first.

Although its domestic market is on the rise, Pakistan's market conditions have not proved welcoming enough to keep foreign investors.

With government support, China's pharmaceutical equipment sector is trekking ahead despite challenges regarding the country's overall perceived product quality.

Surrounded by competition, Vietnam's 2020 vision focuses on building a biotech sector worthy of its Asian neighbors-as well as the growing global biopharmaceutical market